関節リウマチ：デジタルマーケティング動向

当レポートでは、世界の関節リウマチのデジタルマーケティング動向について調査分析し、患者や医療従事者（HCP）向けのブランドウェブサイト、モバイルアプリ、ソーシャルメディアアカウントなど、関節リウマチの製薬会社におけるデジタルマーケティングの主要指標の評価をしています。評価指標には、ウェブサイトのトラフィック量、エンゲージメント、ソース、デジタルディスプレイ広告（DDA）、有料検索エンジン最適化（SEO）、モバイルアプリのダウンロード、ソーシャルメディア投稿の交流などがあります。国別では、米国、4EU（イタリア、フランス、ドイツ、スペイン）、英国、カナダ（EUCAN）が含まれています。

目次

• エグゼクティブサマリー
• 米国の患者ブランドのウェブサイト
• 米国のHCPブランドのウェブサイト
• 米国のデジタルディスプレイ広告と検索エンジン最適化
• 米国のモバイルアプリとソーシャルメディア
• EUCANのブランドのウェブサイト
• EUCANのモバイルアプリとソーシャルメディア

付録

• 調査手法
• 著者について
• お問い合わせ

Abstract

AbbVie's Rinvoq.com achieved the highest total traffic across RA patient brand sites in the US, with over four million visitors from February 2022 to January 2023, followed by AbbVie's Humira.com and Amgen's Enbrel.com. The highest proportion of traffic to branded patient RA websites originated from organic sources, followed by direct. Cimzia.com and Olumiant.com had the highest proportion of traffic from organic search. Xeljanz.com was supported by the most paid SEO at over 8,700 keywords, while Amgen spent the most on DDA for Enbrel.com, at approximately $3 million.

Amgen's Enbrelpro.com achieved the highest traffic across branded RA HCP sites in the US, with approximately 513,000 visits between February 2022 and January 2023. This was followed by Rinvoqhcp.com, with more than 250,000 visits. For DDA, Amgen spent the most on Enbrelpro.com at approximately $244,000. No notable DDA was detected for other HCP sites. Humirapro.com was supported by the most paid SEO at over 5,135 keywords, followed by Enbrelpro.com (3,685) and Rinvoqhcp.com (1,489).

AbbVie's RA.com had the highest traffic of all unbranded RA sites in the US, with over 185,000 visitors from February 2022 to January 2023. The highest proportion of traffic to unbranded RA websites in the US originated from direct search, followed by organic and referral traffic. Amgen spent approximately $9,500 on DDA for its Amgeninflammation.com and invested in 9,610 paid SEO keywords. No notable DDA and SEO was detected for other unbranded RA sites in the US.

Between February 2022 and January 2023, 36 social media posts related to RA were detected from pharma companies in the US, including Janssen, Amgen, Eli Lilly, and Bristol Myers Squibb. The post with the highest interaction (2.2%) was from Eli Lilly's Medical Twitter account highlighting the differences between RA and psoriatic arthritis and the issue of using combination therapy.

AbbVie-care.de in Germany achieved the highest total traffic across branded RA patient sites in EUCAN, with over 700,000 visitors from February 2022 to January 2023. This was followed by Novartis's Ratgeber-rheuma.de (over 220,000 visits).

Roche's Rhumatismes.net in France had the highest total traffic across RA unbranded sites in EUCAN, with approximately 552,000 visitors between February 2022 and January 2023. This was followed by Pfizer's Hilfefuermich.de (333,000 visitors) and Roche's Rheumahelden.de (50,000 visitors). The highest proportion of traffic originated from organic traffic, followed by direct search and social traffic. Eli Lilly's Lillyrhumatologie.fr had the highest proportion of organic traffic (91%), while Pfizer's Hilfefuermich.de had the most direct traffic (60%).

Between February 2022 and January 2023, approximately 120 social media posts related to RA were detected from pharma companies in EUCAN, including Sanofi, Pfizer, Eli Lilly, Merck & Co., and AbbVie. The post with the highest interaction (5.3%) was from the AbbVie Espana Instagram account, which on World Rheumatic Diseases Day 2022 raised awareness of the impact of RA in Spain.

Scope

• This report assesses key digital marketing metrics of pharma assets in rheumatoid arthritis (RA), including branded websites for patients and healthcare professionals (HCPs), unbranded websites, and social media accounts.
• Metrics include website traffic volume, engagement, and source, digital display advertising (DDA), paid search engine optimization (SEO), and social media post interaction. Countries include the US, 4EU (Italy, France, Germany, and Spain), the UK, and Canada (EUCAN).

Reasons to Buy

• Understand the digital marketing competitive landscape in RA, with a view of leading patient and HCP branded assets across different regions.
• See what tactics pharma companies are using to drive traffic to their RA branded and unbranded assets for patient and HCPs, such as DDA and paid SEO.
• Understand what sources of website traffic are generating the most visits to these assets, such as paid SEO, social media, or organic searches.
• Compare top branded assets for patients by how they address and support different patient needs.
• See what pharma social media accounts in RA are the most active and achieving the most engagement.

Table of Contents

Table of Contents

• Executive Summary
• US Patient Branded Websites
• US HCP Branded Websites
• US Unbranded Websites
• US Social Media
• EUCAN Branded Websites
• EUCAN Unbranded Websites
• EUCAN Social Media
• Appendices